{"name":"Professor Mikkel Østergaard","slug":"professor-mikkel-stergaard","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Apremilast Oral Tablet","genericName":"Apremilast Oral Tablet","slug":"apremilast-oral-tablet","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Secukinumab 150 milligram [Cosentyx]","genericName":"Secukinumab 150 milligram [Cosentyx]","slug":"secukinumab-150-milligram-cosentyx","indication":"Moderate to severe plaque psoriasis","status":"marketed"}]}],"pipeline":[{"name":"Apremilast Oral Tablet","genericName":"Apremilast Oral Tablet","slug":"apremilast-oral-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Secukinumab 150 milligram [Cosentyx]","genericName":"Secukinumab 150 milligram [Cosentyx]","slug":"secukinumab-150-milligram-cosentyx","phase":"marketed","mechanism":"Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}